Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review

Global Markets Direct’s, ‘Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

The report provides overview of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Snapshot 5

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Snapshot 5

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Overview 5

Key Information 5

Key Facts 5

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Research and Development Overview 6

Key Therapeutic Areas 6

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products Glance 11

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 11

Phase II Products/Combination Treatment Modalities 11

Phase I Products/Combination Treatment Modalities 12

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 13

IND/CTA Filed Products/Combination Treatment Modalities 13

Preclinical Products/Combination Treatment Modalities 14

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Unknown Stage Pipeline Products 15

Unknown Products/Combination Treatment Modalities 15

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Drug Profiles 16

aminolevulinic acid hydrochloride 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Hitenercept 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

T-0001 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

vincristine sulfate 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

bevacizumab biosimilar 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Fderceptin 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Monoclonal Antibody Conjugate to Target CD30 for Solid Tumor 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Monoclonal Antibody to Inhibit Sclerostin for Osteoporosis 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

paclitaxel 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

etanercept biosimilar 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Analysis 28

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Target 28

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 29

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 30

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 31

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Dormant Projects 32

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 33

Discontinued Pipeline Product Profiles 33

Nifeviroc 33

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Appendix 35

Methodology 35

Coverage 35

Secondary Research 35

Primary Research 35

Expert Panel Validation 35

Contact Us 35

Disclaimer 36

List of Tables

List of Tables

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Key Information 5

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Key Facts 5

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - ...

List of Tables

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Key Information 5

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Key Facts 5

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016 8

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016 9

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016 10

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Phase II, 2016 11

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Phase I, 2016 12

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - IND/CTA Filed, 2016 13

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Preclinical, 2016 14

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Unknown, 2016 15

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Target, 2016 28

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016 29

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016 30

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 31

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016 32

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016 33

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Subsidiaries 34

List of Figures

List of Figures

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016 7

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Stage ...

List of Figures

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016 7

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016 9

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016 10

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Target, 2016 28

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016 29

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016 30

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 31

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports